API Holdings FY26 Results: A Look at the Turnaround and Debt-Free Balance Sheet
· 5 min read · Written by the BuyUnlistedShares desk. Information only, not investment advice.
API Holdings, the parent company behind PharmEasy, Thyrocare, Ascent, and Aknamed, closed FY26 with consolidated revenue of ₹6,869 crore and its first-ever positive EBITDA — while also clearing its outstanding term debt entirely.
Reviewed by the BuyUnlistedShares desk.
For a company that once carried a heavily leveraged balance sheet and years of mounting losses, FY26 marks a genuine turning point. API Holdings — the unlisted parent company behind PharmEasy, Thyrocare, Ascent, and Aknamed — closed the financial year with its first-ever positive group EBITDA and, soon after, a fully repaid term loan.
This piece looks at what actually changed in FY26: the headline numbers, how each business segment performed, and how the company worked its way to a debt-free balance sheet.
Where API Holdings Started From
API Holdings built its healthcare platform around four verticals — consumer pharmacy delivery through PharmEasy, B2B pharmaceutical distribution through Ascent, hospital supply chain through Aknamed, and diagnostics through Thyrocare, acquired in 2021 for roughly ₹4,546 crore. That acquisition was funded partly through high-cost debt, including a loan from Goldman Sachs carrying an annual interest rate in the range of 17–18%, which weighed on the group's finances for the next several years.
Losses were steep in the years that followed: the group's EBITDA loss stood at ₹515 crore in FY24 before narrowing to ₹231 crore in FY25. FY26 is the year this trend finally reversed.
FY26 Headline Numbers
Revenue growth held up consistently across all four quarters of the year, and the swing from a ₹231 crore EBITDA loss to a ₹62.5 crore profit is the largest single-year shift in the company's operating history. It's worth noting that this EBITDA figure is typically reported before ESOP costs and certain exceptional items, which is a standard adjustment for growth-stage companies but one investors and readers should be aware of when comparing it to statutory profit figures.
How Each Business Segment Performed
PharmEasy (Consumer/B2C)
• Gross margins expanded from about 22.8% to 25.7% over the year.
• EBITDA losses more than halved, from ₹86.1 crore to ₹39.4 crore.
• Quarterly losses narrowed steadily, with Q4 FY26 EBITDA margin around -1.5%, close to breakeven.
• Operating expenses still rose about 10.9% year-on-year, pointing to continued spending on marketing and delivery.
Thyrocare (Diagnostics)
• Revenue grew about 20% year-on-year, with roughly 210 million tests processed across 41 labs during the year.
• The franchisee network expanded to over 10,800 partner
• Thyrocare remained the group's most consistently profitable business and a key contributor to overall group performance.
Ascent and Aknamed (B2B Distribution & Hospital Supply Chain)
• The B2B distribution business moved closer to sustainable profitability during the year.
• Both businesses were reported to have reached positive EBITDA in subsequent quarterly updates, supporting the idea that the turnaround is spread across segments rather than concentrated in one.
How API Holdings Became Debt-Free
Alongside the operating turnaround, API Holdings worked through a multi-step process to clear its outstanding debt:
• In September 2025, the company refinanced its legacy high-cost debt from Goldman Sachs and EvolutionX by issuing ₹1,700 crore of non-convertible debentures (NCDs) to 360 ONE.
• By March 2026, the outstanding principal on this facility had been brought down to ₹1,050 crore.
• To fund the final repayment, promoter and holding entity Docon Technologies sold a 9.90% stake in Thyrocare through market transactions, while continuing to hold a controlling 51.02% stake.
• The remaining ₹1,050 crore was fully redeemed in August 2026, rendering the facility debt-free and releasing the pledge on the remaining Thyrocare shares.
The approach is notable because it reduced debt without giving up control of Thyrocare, one of the group's most valuable and consistently profitable assets.
What This Turnaround Signals
Put together, the FY26 numbers tell a fairly consistent story: steady double-digit revenue growth, a shift from loss-making to EBITDA-positive operations, and a cleaner balance sheet with the debt overhang removed. None of these segments turned around overnight — the improvement in PharmEasy's margins, Thyrocare's continued scale-up, and progress at Ascent and Aknamed all played a part.
The next milestone commonly discussed in relation to the group is full-year EBITDA breakeven at the consumer (PharmEasy) segment level, which several market observers link to the company's broader plans, including a potential future public listing. As of now, that remains a forward-looking target rather than a confirmed outcome.
Frequently Asked Questions
1. What is API Holdings?
API Holdings Limited is the unlisted parent company behind several Indian healthcare brands, including PharmEasy (consumer pharmacy), Ascent (B2B pharmaceutical distribution), Aknamed (hospital supply chain), and Thyrocare (diagnostics).
2. What was API Holdings' consolidated revenue in FY26?
The company reported consolidated revenue of ₹6,869 crore in FY26, up 14.3% from ₹6,010 crore in FY25.
3. Did API Holdings turn EBITDA positive in FY26?
Yes. Group EBITDA moved from a loss of ₹231 crore in FY25 to a profit of ₹62.5 crore in FY26 — its first full year of positive EBITDA.
4. Is this EBITDA figure the same as net profit?
No. The reported EBITDA is generally presented before ESOP costs and certain exceptional items. It reflects core operating performance but is not the same as statutory net profit, which would also account for interest, taxes, depreciation, and one-off charges.
5. How did API Holdings become debt-free?
The company refinanced its high-cost legacy debt in September 2025, reduced the outstanding principal to ₹1,050 crore by March 2026 through internal accruals and a partial stake sale in Thyrocare, and fully redeemed the remaining balance in August 2026.
6. Did API Holdings lose control of Thyrocare while repaying its debt?
No. While a 9.90% stake in Thyrocare was sold to help fund the repayment, promoter entity Docon Technologies retained a controlling 51.02% stake in Thyrocare.
7. Which business segment performed best in FY26?
Thyrocare remained the group's most consistently profitable segment, while PharmEasy (consumer) and the B2B distribution business both showed significant improvement, narrowing losses and moving toward profitability.
8. What is the next milestone for API Holdings?
Market commentary frequently points to full-year EBITDA breakeven at the consumer (PharmEasy) segment as the next key milestone, which is often discussed alongside the company's longer-term plans. This remains a forward-looking expectation rather than a confirmed event.
Disclaimer:
This is written for educational and informational purposes only. Nothing here constitutes investment advice or a recommendation to buy or sell securities. All data is sourced from publicly available information. Investments in securities markets are subject to market risks — please read all offer documents carefully before investing.
